Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity

Lancet

Volumn 355, Issue 9215, 2000, Pages 1616-1617

  Landewé, Robert B M ^a   Van Den Borne, Ben E E M ^a   Breedveld, Ferdinand C ^a   Dijkmans, Ben A C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; HOMOCYSTEINE; METHOTREXATE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NOTE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

EID: 0034611896     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02222-4     Document Type: Article

References (5)

1. Wolfe F., Hawley D.J., Pincus T. Methotrexate alters the course of rheumatoid arthritis (RA). Increased survival of methotrexate-treated RA-patients: a 25-year study of 1,842 patients. Arthritis Rheum. 9:1998;188. (suppl).
2. Duell P.B., Malinow M.R. Homocysteine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol. 8:1997;28-34.
3. Roubenoff R., Dellaripa P., Nadeau M.R.et al. Abnormal homocystein metabolism in rheumatoid arthritis. Arthritis Rheum. 40:1997;718-722.
4. Haagsma C.J., Blom H.J., van Riel P.L.C.M.et al. Influence of sulfasalazine, methotrexate and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 58:1999;79-84.
5. van den Borne B.E.E.M., Landewé R.B.M., Houkes I.et al. No increased risk of malignancies and mortality in cyclosporin-A treated rheumatoid arthritis patients. Arthritis Rheum. 41:1998;1930-1937.